10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Consumables: $130.75 million compared to the $127.63 million average estimate based on three analysts. The reported number represents a change of +7% year over year.
• Revenues- Instruments: $7.66 million compared to the $11.32 million average estimate based on three analysts. The reported number represents a change of -47.2% year over year.
• Revenues- Instruments- Single Cell: $3.09 million compared to the $4.99 million average estimate based on three analysts. The reported number represents a change of -46.1% year over year.
• Revenues- Services: $10.68 million versus the three-analyst average estimate of $7.97 million. The reported number represents a year-over-year change of +26%.
• Revenues- Consumables- Single Cell: $88.45 million compared to the $87.71 million average estimate based on three analysts. The reported number represents a change of +3.1% year over year.
• Revenues- Consumables- Spatial: $42.3 million versus the three-analyst average estimate of $39.92 million. The reported number represents a year-over-year change of +16.2%.
• Revenues- Instruments- Spatial: $4.57 million compared to the $6.33 million average estimate based on three analysts. The reported number represents a change of -47.8% year over year.

View all Key Company Metrics for 10x Genomics here>>>

Shares of 10x Genomics have returned +26.7% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research